Actively Recruiting
Study of Flat-Dose Nivolumab 40 mg Combined With AVD Chemotherapy for Adults With Newly Diagnosed Advanced Classic Hodgkin Lymphoma
Led by National Medical Research Radiological Centre of the Ministry of Health of Russia · Updated on 2025-11-26
54
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a combination treatment using a fixed dose of nivolumab 40 mg with the chemotherapy regimen AVD doxorubicin, vinblastine, and dacarbazine for patients newly diagnosed with advanced classic Hodgkin Lymphoma. This Phase 2 study aims to understand response predictors after first-line PD-1 inhibitor therapy and improve management strategies for this condition. Participants will receive six cycles of the Nivo40-AVD treatment, with nivolumab given intravenously on days 1 and 15, along with doxorubicin, vinblastine, and dacarbazine administered on the same schedule. Interim and end-of-treatment PETCT scans will be performed to monitor the disease, but the interim scan results will not influence clinical decisions. Radiation therapy is allowed for patients who show only a partial metabolic response after six cycles based on the Deauville score. During the study, participants will undergo regular PETCT scans to assess treatment response and will be monitored for progression-free survival over two years as the primary outcome. Secondary outcomes include overall survival, complete remission, complete metabolic response, and adverse events, all tracked for two years. The study involves assessments to ensure heart function and overall health, aiming to provide comprehensive safety and efficacy data over the follow-up period.
CONDITIONS
Brief Title
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Research Team
M
Mobil Akhmedov, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here